Molecular diagnostics in esophageal and gastric neoplasms

Muhammad Zulfiqar; Amarpreet Bhalla; Michael Weindel; Vinod B. Shidham

doi:10.1016/j.cll.2013.08.006

Molecular diagnostics in esophageal and gastric neoplasms

Muhammad Zulfiqar, Amarpreet Bhalla, Michael Weindel, Vinod B. Shidham

Research output: Contribution to journal › Review article › peer-review

4 Scopus citations

Abstract

Esophageal carcinoma is the most rapidly increasing tumor in incidence in the United States. It has an established association with a precursor lesion (Barrett esophagus). Gastric carcinoma (GC) is the second leading cause of cancer death in the world. The prognosis for patients with advanced stage GC and esophageal carcinoma is poor. Human epidermal growth factor 2 (HER-2) overexpression is seen in gastroesophageal junction carcinoma and a subset of GC. HER-2 overexpressing tumors are eligible for HER-2 targeted therapies, which lead to a better survival in these patients.

Original language	English (US)
Pages (from-to)	867-873
Number of pages	7
Journal	Clinics in Laboratory Medicine
Volume	33
Issue number	4
DOIs	https://doi.org/10.1016/j.cll.2013.08.006
State	Published - Dec 2013
Externally published	Yes

Keywords

Adenocarcinoma
Esophagus
Gastric carcinoma
HER-2
Molecular genetics
Squamous cell carcinoma
Trastuzumab

ASJC Scopus subject areas

Clinical Biochemistry
Biochemistry, medical

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.cll.2013.08.006

Cite this

@article{41891f8308c34e8591f81331caad6fd3,

title = "Molecular diagnostics in esophageal and gastric neoplasms",

abstract = "Esophageal carcinoma is the most rapidly increasing tumor in incidence in the United States. It has an established association with a precursor lesion (Barrett esophagus). Gastric carcinoma (GC) is the second leading cause of cancer death in the world. The prognosis for patients with advanced stage GC and esophageal carcinoma is poor. Human epidermal growth factor 2 (HER-2) overexpression is seen in gastroesophageal junction carcinoma and a subset of GC. HER-2 overexpressing tumors are eligible for HER-2 targeted therapies, which lead to a better survival in these patients.",

keywords = "Adenocarcinoma, Esophagus, Gastric carcinoma, HER-2, Molecular genetics, Squamous cell carcinoma, Trastuzumab",

author = "Muhammad Zulfiqar and Amarpreet Bhalla and Michael Weindel and Shidham, {Vinod B.}",

year = "2013",

month = dec,

doi = "10.1016/j.cll.2013.08.006",

language = "English (US)",

volume = "33",

pages = "867--873",

journal = "Clinics in Laboratory Medicine",

issn = "0272-2712",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - Molecular diagnostics in esophageal and gastric neoplasms

AU - Zulfiqar, Muhammad

AU - Bhalla, Amarpreet

AU - Weindel, Michael

AU - Shidham, Vinod B.

PY - 2013/12

Y1 - 2013/12

N2 - Esophageal carcinoma is the most rapidly increasing tumor in incidence in the United States. It has an established association with a precursor lesion (Barrett esophagus). Gastric carcinoma (GC) is the second leading cause of cancer death in the world. The prognosis for patients with advanced stage GC and esophageal carcinoma is poor. Human epidermal growth factor 2 (HER-2) overexpression is seen in gastroesophageal junction carcinoma and a subset of GC. HER-2 overexpressing tumors are eligible for HER-2 targeted therapies, which lead to a better survival in these patients.

AB - Esophageal carcinoma is the most rapidly increasing tumor in incidence in the United States. It has an established association with a precursor lesion (Barrett esophagus). Gastric carcinoma (GC) is the second leading cause of cancer death in the world. The prognosis for patients with advanced stage GC and esophageal carcinoma is poor. Human epidermal growth factor 2 (HER-2) overexpression is seen in gastroesophageal junction carcinoma and a subset of GC. HER-2 overexpressing tumors are eligible for HER-2 targeted therapies, which lead to a better survival in these patients.

KW - Adenocarcinoma

KW - Esophagus

KW - Gastric carcinoma

KW - HER-2

KW - Molecular genetics

KW - Squamous cell carcinoma

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84888203978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888203978&partnerID=8YFLogxK

U2 - 10.1016/j.cll.2013.08.006

DO - 10.1016/j.cll.2013.08.006

M3 - Review article

C2 - 24267191

AN - SCOPUS:84888203978

SN - 0272-2712

VL - 33

SP - 867

EP - 873

JO - Clinics in Laboratory Medicine

JF - Clinics in Laboratory Medicine

IS - 4

ER -

Molecular diagnostics in esophageal and gastric neoplasms

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this